PL
NVAX icon

Parkwood LLC’s Novavax NVAX Stock Holding History

Parkwood LLC’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,974
Closed -$735K – 169
2022
Q1 		$735K Buy
9,974
+3,047
+44% +$272K 0.12% 95
2021
Q4 		$991K Buy
6,927
+93
+1% +$16K 0.17% 79
2021
Q3 		$1.42M Sell
6,834
-3,783
-36% -$834K 0.17% 83
2021
Q2 		$2.25M Buy
10,617
+5,463
+106% +$1M 0.26% 73
2021
Q1 		$934K Sell
5,154
-373
-7% -$74.3K 0.17% 75
2020
Q4 		$616K Buy
+5,527
New +$587K 0.07% 100

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parkwood LLC's NVAX Position: Q2 2022 in Review

Parkwood LLC sold out of Novavax (NVAX) in Q2 2022, closing a stake of 9,974 shares — an estimated $735K sold.

Parkwood LLC first reported a position in NVAX in Q4 2020 and held it in 6 quarters. The position peaked at $2.25M in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

  • Parkwood LLC reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
  • Parkwood LLC sold 9,974 Novavax shares in Q2 2022, an estimated $735K.
  • Parkwood LLC first reported a position in Novavax in Q4 2020 and held it in 6 quarters.
  • Parkwood LLC's Novavax position peaked at $2.25M in Q2 2021.
  • 325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Parkwood LLC's 13F filing for Q2 2022, filed 15 Aug 2022.